Unidade Local De Saude De Entre O Douro E Vouga E.P.E.

At Unidade Local De Saude De Entre O Douro E Vouga E.P.E., the strongest area of research is cardiology, with studies focused on acute coronary syndrome, atrial fibrillation, heart failure, hypertension, and broader atherosclerotic cardiovascular disease. These trials are mainly designed to test new treatments, lower the risk of major cardiovascular events, and improve care for people with established or high-risk heart disease.

• Preventing stroke, heart attack, and other major cardiovascular events
• Evaluating therapies for heart failure, hypertension, and atrial fibrillation
• Studying medicines aimed at reducing inflammation and vascular risk

Several studies also address patients with type 2 diabetes, obesity, and severe hypertriglyceridemia, reflecting a broad effort to improve long-term cardiovascular health.

Research in digestive system diseases includes trials for Crohn's disease, ulcerative colitis, and colorectal cancer. The main goal is to evaluate new therapies that can control inflammation better, support remission, and improve outcomes for people living with chronic intestinal disease.

• Testing treatments for moderately to severely active Crohn's disease
• Assessing options for ulcerative colitis maintenance and response
• Exploring treatment effectiveness in colorectal cancer

These studies show an active interest in both symptom control and longer-term disease management within gastrointestinal care.

This site is also involved in trials across immune system diseases and immune system phenomena, including conditions such as Crohn's disease, ulcerative colitis, multiple sclerosis, and chronic rhinosinusitis with nasal polyps. The research is aimed at understanding how immune-targeted treatments can reduce inflammation and improve daily functioning.

• Studying new immunology-based therapies
• Evaluating treatments for inflammatory and autoimmune conditions
• Improving long-term control of immune-driven disease

Work in this area highlights the site’s broader focus on precision treatment for diseases linked to abnormal immune activity.

Clinical research in nervous system diseases covers multiple sclerosis, epilepsy, and agitation in dementia of the Alzheimer’s type. These trials are designed to test therapies that may reduce relapses, control seizures, and improve symptoms that affect quality of life.

• Evaluating treatments for relapsing and progressive multiple sclerosis
• Studying medicines for focal onset epilepsy and generalized tonic-clonic seizures
• Assessing options for behavioral symptoms in Alzheimer’s disease

These studies reflect a strong interest in both neurological disease control and support for patients with complex, chronic conditions.

The site contributes to oncology research in neoplasms such as advanced gastric or gastroesophageal junction cancer, metastatic colorectal cancer, and high-risk prostate cancer. The purpose of these trials is to compare new cancer treatments with standard care and determine whether they can improve survival and slow disease progression.

• Testing therapies for gastrointestinal cancers
• Studying treatment strategies in prostate cancer
• Evaluating whether new combinations can improve cancer outcomes

This area adds a valuable cancer research dimension to the broader clinical portfolio at the hospital.

Additional studies at Unidade Local De Saude De Entre O Douro E Vouga E.P.E. focus on eye diseases and respiratory tract diseases, including thyroid eye disease and chronic rhinosinusitis with nasal polyps. These trials aim to improve symptom relief, reduce inflammation, and assess whether newer therapies can offer better disease control.

• Assessing treatment options for thyroid eye disease
• Studying therapies for nasal polyps and chronic sinus inflammation
• Exploring ways to improve comfort and function in affected patients

Although smaller in number, these studies broaden the site’s research reach beyond cardiovascular and gastrointestinal care.

Research in nutritional and metabolic diseases includes obesity, severe hypertriglyceridemia, and type 2 diabetes with related cardiovascular risk. The trials are intended to evaluate whether new therapies can improve metabolic health and reduce the chance of future heart complications.

• Testing treatments for weight-related and lipid disorders
• Studying metabolic risk in people with diabetes and cardiovascular disease
• Supporting prevention of long-term complications

This research area connects closely with the site’s cardiovascular work, especially for patients with overlapping risk factors.